The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection.

Attending rounds: microangiopathic hemolytic anemia with renal insufficiency. Clin J Am Soc Nephrol (2011) 0.81

Thrombotic microangiopathy in adult-onset Still's disease: case report and review of the literature. Wien Klin Wochenschr (2009) 0.77

Thrombotic microangiopathy: An unusual cause of renal failure in rheumatoid arthritis. Indian J Nephrol (2017) 0.75

Refractory thrombotic thrombocytopenic purpura associated with oral contraceptives and factor V Leiden: a case report. Cases J (2009) 0.75

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48

ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood (2003) 3.88

Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.87

Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood (2009) 3.18

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med (2016) 2.83

von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood (2010) 2.82

Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med (2003) 2.76

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood (2004) 2.42

Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30

Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood (2008) 2.17

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood (2002) 1.93

Parental communication and youth sexual behaviour. J Adolesc (2006) 1.87

Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87

Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood (2012) 1.87

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion (2004) 1.84

The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol (2010) 1.83

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood (2010) 1.76

Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med (2004) 1.69

Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood (2004) 1.67

Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med (2003) 1.64

Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol (2009) 1.56

Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf (2009) 1.52

Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost (2008) 1.50

Youth-parent communication and youth sexual behavior: implications for physicians. Fam Med (2006) 1.50

Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. Am J Hematol (2003) 1.50

Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood (2014) 1.47

Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic purpura: A report of 10 patients and a systematic review of published cases. Oncologist (2007) 1.45

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39

The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract (2004) 1.34

Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood (2002) 1.29

Relationships among youth assets and neighborhood and community resources. Health Educ Behav (2005) 1.28

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood (2005) 1.27

Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion (2012) 1.27

Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood (2004) 1.20

Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (2007) 1.19

Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer (2013) 1.16

Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion (2006) 1.14

C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med (2002) 1.14

Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood (2013) 1.13

Reliability and validity of the youth asset survey (YAS). J Adolesc Health (2002) 1.12

Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol (2011) 1.10

The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol (2004) 1.09

Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion (2009) 1.09

Thrombocytopenia as an adverse effect of complementary and alternative medicines, herbal remedies, nutritional supplements, foods, and beverages. Eur J Haematol (2010) 1.08

Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med (2014) 1.02

Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J (2007) 1.00

Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood (2002) 1.00

Is factor V Leiden a risk factor for thrombotic microangiopathies without severe ADAMTS 13 deficiency? Thromb Haemost (2005) 0.99

Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis (2002) 0.99

Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb Haemost (2006) 0.99

Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99

Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion (2004) 0.98

Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res (2002) 0.98

Adolescent tobacco use: the protective effects of developmental assets. Am J Health Promot (2002) 0.96

ADAMTS13 activity in sickle cell disease. Am J Hematol (2006) 0.95

Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93

Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher (2006) 0.93

Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol (2011) 0.93

ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol (2003) 0.92

D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis (2009) 0.92

von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol (2004) 0.92

Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol (2010) 0.92

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica (2013) 0.92

The association between multiple youth assets and sexual behavior. Am J Health Promot (2004) 0.92